Aloisine A is a cell permeable, potent, selective, reversible, and ATP-competitive inhibitor of Cdc2 (CDK1)/cyclin B (IC50 = 150nM), Cdk2/cyclin A (IC50 = 120nM), Cdk2/cyclin E (IC50 = 400nM), Cdk5/p25 (IC50 = 200nM), Cdk5/p35 (IC50 = 160nM), and GSK-3α (IC50 = 500nM). Aloisine A also inhibits GSK-3β (IC50 = 650nM) and JNK (c-Jun N-terminal kinase) (IC50~3-10μM). Aloisine A is a poor inhibitor of CK1, CK2, Cdk4/cyclin D1, MAPKK, PKA, PKG, PKCs and c-raf (IC50 ≥ 100μM). Aloisine A blocks the cell cycle in both G1 and G2 phase. Aloisine A is an activator of CFTR.
1. Mettey, Yvette., et al., 2003. Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects. Journal of medicinal chemistry. 46(2): 222-36. PMID: 12519061
2. Noel, Sabrina., et al., 2006. Discovery of pyrrolo[2,3-b]pyrazines derivatives as submicromolar affinity activators of wild type, G551D, and F508del cystic fibrosis transmembrane conductance regulator chloride channels. The Journal of pharmacology and experimental therapeutics. 319(1): 349-59. PMID: 16829626
3. Corbel, Caroline., et al., 2009. Identification of potential cellular targets of aloisine A by affinity chromatography. Bioorganic & medicinal chemistry. 17(15): 5572-82. PMID: 19596197
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.